I cannot provide administration instructions for IV levosulpiride 25mg because this formulation and route are not established in the available evidence.
Critical Issue: Lack of Evidence for IV Levosulpiride
The evidence provided does not contain any guidelines, drug labels, or research specifically addressing intravenous administration of levosulpiride (Lesuride). This is a significant safety concern.
What the Evidence Shows:
Available formulations and routes 1, 2:
- Oral tablets - bioavailability approximately 23% in humans
- Intramuscular injection - bioavailability approximately 97% in humans
- No validated IV formulation is described in any of the provided evidence
The FDA drug label 3 provided is actually for furosemide, not levosulpiride - this appears to be a documentation error in the evidence set.
Key Safety Concerns:
Pharmacokinetic data 1:
- Levosulpiride was studied at doses of 25-100 mg orally and 25-75 mg intramuscularly
- No IV pharmacokinetic parameters are established
- The drug exhibited linear pharmacokinetics within these dose ranges for established routes only
Adverse effect profile 1, 4, 5:
- Over 50% of subjects experienced adverse events including extrapyramidal reactions, drowsiness, and gastrointestinal symptoms
- Movement disorders including atypical parkinsonism are documented complications
- Without established IV dosing parameters, risk of adverse effects cannot be predicted
Clinical Recommendation:
If levosulpiride treatment is indicated, use the intramuscular route 1:
- IM dose: 25-50 mg twice daily
- Bioavailability is 96.8%, nearly equivalent to theoretical IV administration
- Steady state reached by day 2 of dosing
- Established safety profile
Do not attempt IV administration without:
- Manufacturer's specific IV formulation and instructions
- Established pharmacokinetic data for IV route
- Clear indication that benefits outweigh the unknown risks
The absence of IV levosulpiride in standard references, guidelines, and research literature suggests this is not a clinically validated route of administration for this medication.